BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bhardwaj S, Canlas K, Kahi C, Temkit M, Molleston J, Ober M, Howenstine M, Kwo PY. Hepatobiliary abnormalities and disease in cystic fibrosis: epidemiology and outcomes through adulthood. J Clin Gastroenterol. 2009;43:858-864. [PMID: 19525864 DOI: 10.1097/mcg.0b013e31819e8bbd] [Cited by in Crossref: 27] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Cheng K, Ashby D, Smyth RL. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst Rev 2017;9:CD000222. [PMID: 28891588 DOI: 10.1002/14651858.CD000222.pub4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
2 Ayoub F, Trillo-Alvarez C, Morelli G, Lascano J. Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease. World J Hepatol 2018; 10(1): 34-40 [PMID: 29399276 DOI: 10.4254/wjh.v10.i1.34] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
3 Costa PC, Barreto CC, Pereira L, Lobo ML, Costa MA, Lopes AI. Cystic fibrosis-related liver disease: a single-center experience. Pediatr Rep 2011;3:e21. [PMID: 22053265 DOI: 10.4081/pr.2011.e21] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
4 Poetter-Lang S, Staufer K, Baltzer P, Tamandl D, Muin D, Bastati N, Halilbasic E, Hodge JC, Trauner M, Kazemi-Shirazi L, Ba-Ssalamah A. The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. Eur Radiol 2019;29:1048-58. [PMID: 30054796 DOI: 10.1007/s00330-018-5650-5] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
5 Koh C, Sakiani S, Surana P, Zhao X, Eccleston J, Kleiner DE, Herion D, Liang TJ, Hoofnagle JH, Chernick M, Heller T. Adult-onset cystic fibrosis liver disease: Diagnosis and characterization of an underappreciated entity. Hepatology. 2017;66:591-601. [PMID: 28422310 DOI: 10.1002/hep.29217] [Cited by in Crossref: 51] [Cited by in F6Publishing: 41] [Article Influence: 10.2] [Reference Citation Analysis]
6 De Lisle RC, Borowitz D. The cystic fibrosis intestine. Cold Spring Harb Perspect Med. 2013;3:a009753. [PMID: 23788646 DOI: 10.1101/cshperspect.a009753] [Cited by in Crossref: 95] [Cited by in F6Publishing: 90] [Article Influence: 10.6] [Reference Citation Analysis]
7 Kwo PY. Shortness of breath in the patient with chronic liver disease. Clin Liver Dis 2012;16:321-9. [PMID: 22541701 DOI: 10.1016/j.cld.2012.03.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Flass T, Narkewicz MR. Cirrhosis and other liver disease in cystic fibrosis. J Cyst Fibros. 2013;12:116-124. [PMID: 23266093 DOI: 10.1016/j.jcf.2012.11.010] [Cited by in Crossref: 95] [Cited by in F6Publishing: 79] [Article Influence: 9.5] [Reference Citation Analysis]
9 Lynch JP 3rd, Sayah DM, Belperio JA, Weigt SS. Lung transplantation for cystic fibrosis: results, indications, complications, and controversies. Semin Respir Crit Care Med 2015;36:299-320. [PMID: 25826595 DOI: 10.1055/s-0035-1547347] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 4.9] [Reference Citation Analysis]
10 Murphy MP, Caraher E. Current and Emerging Therapies for the Treatment of Cystic Fibrosis or Mitigation of Its Symptoms. Drugs R D 2016;16:1-17. [PMID: 26747453 DOI: 10.1007/s40268-015-0121-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
11 Więcek S, Woś H, Pogorzelski A, Kordys-Darmolinska B, Mazurek H, Grzybowska-Chlebowczyk U. Assessment of Selected Parameters of Liver Fibrosis and Inflammation in Patients with Diagnosed Cystic Fibrosis. Mediators Inflamm 2020;2020:5696185. [PMID: 32308556 DOI: 10.1155/2020/5696185] [Reference Citation Analysis]
12 Fiorotto R, Strazzabosco M. Pathophysiology of Cystic Fibrosis Liver Disease: A Channelopathy Leading to Alterations in Innate Immunity and in Microbiota. Cell Mol Gastroenterol Hepatol 2019;8:197-207. [PMID: 31075352 DOI: 10.1016/j.jcmgh.2019.04.013] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
13 Squirell E, Lockyer J. Cystic fibrosis liver disease in Newfoundland and Labrador: a prevalence study. CanLivJ 2021;4:33-7. [DOI: 10.3138/canlivj-2020-0012] [Reference Citation Analysis]
14 Sakiani S, Kleiner DE, Heller T, Koh C. Hepatic Manifestations of Cystic Fibrosis. Clin Liver Dis 2019;23:263-77. [PMID: 30947876 DOI: 10.1016/j.cld.2018.12.008] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]